In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect adalimumab (Humira), an anti–tumor necrosis factor therapy in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect of adalimumab (Humira), an anti—tumor necrosis factor therapy, in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
This study was a multicenter, non-interventional, open cohort trial that utilized data from the Rheumatic Diseases Portuguese Register. Patients included in the study were adults with PsA who were diagnosed according to the Classification Criteria for Psoriatic Arthritis, were registered in the database between June 2008 and June 2016, and had received adalimumab therapy for 3 or more months.
In total, 126 patients were included in the study. Participants with early PsA had a mean disease duration of 2.6 years (±1.3 years) and were significantly younger and began treatment with biologics earlier than patients with late PsA. Conversely, patients with late-stage PsA had a mean disease duration of 13.4 years (±8.1 years).
A Psoriasis Arthritis Response Criteria (PsARC) response was achieved by 72.9% of patients treated with adalimumab at 3 months. Of the participants receiving adalimumab at month 24, 85.4% had a PsARC response. More patients with early PsA achieved PsARC at 3 months than did patients with late PsA (88% versus 62.2%; P =.022) and 24 months (100% versus 75.8%; P =.044).
The early PsA group achieved, on average, a PsARC response 3.8 months after initial treatment with adalimumab; the mean time to PsARC response in patients with late PsA was 7.4 months.
It is important to note that, during the study follow-up, 51 patients (37.8%) discontinued treatment with adalimumab. The mean duration of therapy until discontinuation was 25.7 months (± 21.2 months): 14.7 months (±16.5 months) for patients with early PsA and 29.9 months (± 22.6 months) for those with late PsA (P =.033).
The most common reason for therapy discontinuation was lack of efficacy, and the proportion of patients with early PsA (31.7%) and late PsA (40.0%) who discontinued adalimumab was similar.
Researchers found that, in this real-world clinical setting, patients with PsA who had a shorter disease duration achieved better results after treatment with adalimumab than did patients with a longer disease duration. This finding adds support to the idea that shorter symptom duration and earlier treatment with adalimumab could lead to a more favorable outcome in patients with PsA. Researchers did note, however, that further studies are needed to confirm these results.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarized the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.